Lmnl stock - How To Discuss

Lmnl stock

Who bought LMNL stock? In the past quarter, LMNL shares were sold by several institutional investors, including Susquehanna Fundamental Investments LLC. Which major investors are buying shares in Liminal BioSciences?

Should you hold liminal Biosciences (LMNL) stock?

Wall Street analysts agree that investors should own shares of Liminal BioSciences. The note states that analysts believe that investors should hold existing positions in the LMNL, but not buy additional shares or sell existing shares.

Will limliminal Biosciences (LMNL) gain on rising earnings estimates?

Liminal BioSciences Inc. (LMNL) is currently technically oversold, so heavy selling pressure may have eased. This, combined with Wall Street analysts' strong consensus for higher earnings estimates, could lead to a reversal in the stock's trend.

What is liminal Biosciences' (lbsi) stock price potential next year?

Their forecasts range from $ to $, on average they expect the Liminal BioSciences stock to rise to $ next year. This indicates a possible increase in the current value of the share.

What is the price targets for LMNL stock?

The 12-month average price target for LMNL's shares is dollars, according to analysts. The high target price for LMNL is $ and the low target price for LMNL is $. Show historical targets for the LMNL award.

Who bought lmnl stock after hours

Analysts' average dollar price target suggests potential upside from current levels. The LMNL scores 3 out of 10 on the TipRanks smart score, suggesting the stock is likely lagging the market.

What is the high and low price target for LMNL?

LMNL high target price - $ and LMNL low target price - $ View history LMNL target price What is the advantage of LMNL?

What is liminal Biosciences Inc (LMNL)?

Liminal BioSciences Inc. (Nasdaq: LMNL) (Liminal BioSciences of Company), a clinical-stage biopharmaceutical company, today announced financial results for its fourth quarter and fiscal year ended December 31, 2020.

Did liminal Biosciences close the sale of its plasma collection centers?

Liminal BioSciences (LMNL) has announced the sale of its plasma collection centers to Prometic Plasma Resources Inc. and Prometic Plasma Resources (USA) Inc. rounded. Liminal BioSciences' stake rose to USD Friday, but has been falling for some time now. Liminal received $17 million in cash for the sale of the Kedrion facility.

Is liminal Biosciences (LMNL) a buy or sell?

Is LMNL currently being purchased? The Liminal BioSciences (NASDAQ: LMNL) consensus rating cannot be bought, based on 4 analyst reviews last year. Instead, LMNL's consensus assessment is maintained.

What are analysts' target prices for liminal Biosciences' stock?

4 analysts have published 12-month target prices for the shares of Liminal BioSciences. Their forecasts range from $ to $, on average they expect the shares of Liminal BioSciences to rise as much as $ in the next 12 months. This indicates a possible increase in the current price of the stock.

What is the short interest in limliminal Biosciences (LMI)?

Liminal BioSciences short-term interest rates rose in August. On August 13, there were short bets of 859,900 shares, compared to 331,800 shares on July 29. With an average daily trading volume of 1,680,000 shares, the short-term interest rate is currently days.

Should you hold liminal biosciences (lmnl) stock video

The note states that analysts believe that investors should hold existing positions in the LMNL, but not buy additional shares or sell existing shares. Check out Liminal BioSciences' analyst notes or browse the top-rated promotions. What is Liminal BioSciences MarketBeat's Preferred Share?

What are the price targets for liminal Biosciences' shares?

Four brokers have set annual target prices for the shares of Liminal BioSciences. Their forecasts range from $ to $, on average they expect the Liminal BioSciences stock to rise to $ next year. This indicates a possible increase in the current value of the shares.

What happened to liminal Biosciences?

Liminal BioSciences Inc. (Nasdaq: LMNL) (Liminal BioSciences of Company) announced today that Kedrion (Kedrion) has exercised its option to acquire the remainder of the company's plasma business under the terms of the share purchase agreement between the company and Kedrion.

When is liminal Biosciences expected to release its next quarterly earnings?

Liminal BioSciences is expected to publish its next quarterly report on Thursday, November 11, 2021. View the revenue forecast for Liminal BioSciences.

How much does liminal Biosciences make a year?

Liminal BioSciences has a market cap of millions of dollars and profits of millions per year. The company earns $88,030 per year in net income (earnings) or (dollars) depending on earnings per share. How many employees does Liminal BioSciences have? Liminal BioSciences employs 251 people worldwide.

Lmnl stock predictions

LMNL Stock Trend The stock is in the midst of a very broad and bearish short-term trend and there are signs of further declines. Given the current short-term trend, the stock should fall in the next 3 months and there is a 90% chance that it will remain between $ and $ at the end of those 3 months.